122 related articles for article (PubMed ID: 37798145)
1. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Minami K; Osawa T; Kojima T; Hara T; Eto M; Takeuchi A; Nakai Y; Ueda K; Ozawa M; Uemura M; Ohba K; Tamura K; Shindo T; Nakagomi H; Takahashi A; Anai S; Yokomizo A; Morizane S; Kimura T; Shimazui T; Miyauchi Y; Mitsuzuka K; Hara H; Yoshimura K; Shiina H; Ito YM; Murai S; Nishiyama H; Shinohara N; Kitamura H;
Urol Oncol; 2023 Nov; 41(11):458.e9-458.e19. PubMed ID: 37798145
[TBL] [Abstract][Full Text] [Related]
2. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
3. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H;
Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266
[TBL] [Abstract][Full Text] [Related]
4. Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib.
Mizuno R; Mikami S; Takamatsu K; Shinojima T; Kikuchi E; Oya M
Jpn J Clin Oncol; 2017 Dec; 47(12):1170-1174. PubMed ID: 28977627
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
7. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
9. Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma.
Nozawa M; Sugimoto K; Ohzeki T; Minami T; Shimizu N; Adomi S; Saito Y; Nose K; Yoshimura K; Uemura H
Int J Clin Oncol; 2016 Aug; 21(4):748-755. PubMed ID: 26694813
[TBL] [Abstract][Full Text] [Related]
10. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.
Miyake H; Harada K; Imai S; Miyazaki A; Fujisawa M
Int J Clin Oncol; 2015 Aug; 20(4):796-801. PubMed ID: 25424248
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
[TBL] [Abstract][Full Text] [Related]
12. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
14. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
[TBL] [Abstract][Full Text] [Related]
15. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
16. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
[TBL] [Abstract][Full Text] [Related]
17. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Grünwald V; Hilser T; Meiler J; Goebell PJ; Ivanyi P; Strauss A; Hartmann A; Bedke J; Bergmann L
Oncol Res Treat; 2022; 45(5):272-280. PubMed ID: 35045416
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
Miyake H; Harada KI; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
[TBL] [Abstract][Full Text] [Related]
19. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N;
Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135
[TBL] [Abstract][Full Text] [Related]
20. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
